ConvaTec Group PLC (LON:CTEC - Get Free Report) has earned a consensus rating of "Moderate Buy" from the nine analysts that are currently covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company. The average 1-year price objective among brokerages that have updated their coverage on the stock in the last year is GBX 306.
CTEC has been the topic of a number of research analyst reports. Citigroup lowered their target price on ConvaTec Group from GBX 250 to GBX 230 and set a "neutral" rating on the stock in a report on Monday, May 18th. Royal Bank Of Canada reissued an "outperform" rating and issued a GBX 315 price target on shares of ConvaTec Group in a report on Monday, August 3rd. JPMorgan Chase & Co. reduced their price objective on shares of ConvaTec Group from GBX 307 to GBX 294 and set an "overweight" rating for the company in a research report on Friday, May 22nd. UBS Group restated a "buy" rating and set a GBX 375 price objective on shares of ConvaTec Group in a research report on Monday, May 18th. Finally, Deutsche Bank Aktiengesellschaft reaffirmed a "buy" rating and issued a GBX 315 price objective on shares of ConvaTec Group in a research note on Wednesday, August 5th.
Read Our Latest Report on ConvaTec Group
ConvaTec Group Stock Up 0.1%
CTEC opened at GBX 230.11 on Thursday. The company has a debt-to-equity ratio of 121.83, a quick ratio of 0.96 and a current ratio of 1.93. The company has a market capitalization of £4.50 billion, a PE ratio of 26.76, a P/E/G ratio of 0.93 and a beta of 0.77. The stock's fifty day moving average is GBX 223.12 and its 200-day moving average is GBX 221.22. ConvaTec Group has a one year low of GBX 193 and a one year high of GBX 259.30.
Insiders Place Their Bets
In other ConvaTec Group news, insider Tobias Hestler purchased 50,000 shares of the firm's stock in a transaction on Thursday, August 6th. The shares were purchased at an average price of GBX 226 per share, for a total transaction of £113,000. Insiders own 0.98% of the company's stock.
ConvaTec Group Company Profile
(
Get Free Report)
ConvaTec Group PLC engages in the development, manufacturing, and sale of medical products, services, and technologies in Europe, North America, and internationally. The company offers advanced wound dressings and skin care products for the management of acute and chronic wounds resulting from various conditions, such as diabetes, and acute conditions resulting from traumatic injury and burns. It also provides ostomy care solutions, including devices, accessories, and services for people with a stoma resulting from colorectal cancer, inflammatory bowel disease, and bladder cancer.
See Also

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider ConvaTec Group, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ConvaTec Group wasn't on the list.
While ConvaTec Group currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.
This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.